Co-Authors
This is a "connection" page, showing publications co-authored by Jean-Marc Rolain and Jean-Christophe Lagier.
Connection Strength
1.340
-
Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 Jul - Aug; 36:101791.
Score: 0.222
-
Culturing the human microbiota and culturomics. Nat Rev Microbiol. 2018 05 01; 16:540-550.
Score: 0.191
-
Genome sequence and description of Clostridium niameyense sp. nov., isolated from a human with marasmus in Nigeria. New Microbes New Infect. 2018 Jul; 24:26-31.
Score: 0.190
-
Microbial Culturomics Application for Global Health: Noncontiguous Finished Genome Sequence and Description of Pseudomonas massiliensis Strain CB-1T sp. nov. in Brazil. OMICS. 2018 02; 22(2):164-175.
Score: 0.181
-
Noncontiguous finished genome sequence and description of Enterococcus massiliensis sp. nov. New Microbes New Infect. 2016 Jul; 12:90-5.
Score: 0.167
-
Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients? J Microbiol Immunol Infect. 2021 Oct; 54(5):997-1000.
Score: 0.058
-
Natural history of COVID-19 and therapeutic options. Expert Rev Clin Immunol. 2020 12; 16(12):1159-1184.
Score: 0.058
-
Clinical efficacy of chloroquine derivatives in COVID-19 infection: comparative meta-analysis between the big data and the real world. New Microbes New Infect. 2020 Nov; 38:100709.
Score: 0.055
-
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France. Travel Med Infect Dis. 2020 May - Jun; 35:101738.
Score: 0.055
-
Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020 Mar - Apr; 34:101663.
Score: 0.055
-
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul; 56(1):105949.
Score: 0.055
-
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 04; 55(4):105932.
Score: 0.054